FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021505546> ?p ?o ?g. }

• W2021505546 endingPage "603" @default.
• W2021505546 startingPage "594" @default.
• W2021505546 abstract "Xamoterol is a new orally active partial β-adrenoceptor agonist. Its kinetics, hemodynamic and metabolic effects, and cardioselectivity were investigated in eight normal subjects. Plasma xamoterol concentrations after 100 µg/kg iv declined biexponentially over 8 hr and t½β averaged 2.6 hr. Resting heart rate (HR) increased slightly in the supine position but was unchanged on sitting. Systolic blood pressure (SBP) rose by 5 to 10 mm Hg and cardiac index (CI) rose 15% to 20%. Both parameters were above control values 6 hr after dosing, when plasma xamoterol concentrations had fallen to about 10 ng/ml. There were no changes in diastolic or mean arterial pressure (MAP). During graded exercise the effects of xamoterol on HR and SBP were the reverse of those at rest, with lowering of exercise HR and SBP at higher work loads. CI during exercise was not altered by xamoterol. Doses of xamoterol were calculated from the kinetic data to give plasma concentrations of 100, 200, 400, and 800 ng/ml. HR and blood pressure effects at each xamoterol level were compared before and after inhibition of cardiovascular reflexes with prazosin, atropine, and Clonidine. Hemodynamic effects of xamoterol and isoproterenol were compared. Before autonomic block xamoterol increased HR by 10 bpm and MAP by 7 mm Hg at the highest dose. After autonomie block there was a 200% to 300% rise in HR at each dose and MAP still rose. The rise in MAP after block could be entirely accounted for by a 23% increase in CI because total peripheral resistance did not change. The effects of isoproterenol after autonomic block were a rise in HR and a fall in MAP. Metabolic responses to xamoterol were measured at the four dose levels. There was a dose-related increase in nonesterified fatty acids and a fall in plasma lactate levels but no changes in plasma renin activity or blood glucose. Results suggest that xamoterol is a cardio selective partial β-adrenoceptor agonist in man. Clinical Pharmacology and Therapeutics (1984) 35, 594–603; doi:10.1038/clpt.1984.82" @default.
• W2021505546 created "2016-06-24" @default.
• W2021505546 creator A5004142633 @default.
• W2021505546 creator A5054837665 @default.
• W2021505546 creator A5066602408 @default.
• W2021505546 creator A5067667648 @default.
• W2021505546 date "1984-05-01" @default.
• W2021505546 modified "2023-10-16" @default.
• W2021505546 title "Cardioselectivity, kinetics, hemodynamics, and metabolic effects of xamoterol" @default.
• W2021505546 doi "https://doi.org/10.1038/clpt.1984.82" @default.
• W2021505546 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6143634" @default.
• W2021505546 hasPublicationYear "1984" @default.
• W2021505546 type Work @default.
• W2021505546 sameAs 2021505546 @default.
• W2021505546 citedByCount "36" @default.
• W2021505546 crossrefType "journal-article" @default.
• W2021505546 hasAuthorship W2021505546A5004142633 @default.
• W2021505546 hasAuthorship W2021505546A5054837665 @default.
• W2021505546 hasAuthorship W2021505546A5066602408 @default.
• W2021505546 hasAuthorship W2021505546A5067667648 @default.
• W2021505546 hasConcept C125567185 @default.
• W2021505546 hasConcept C126322002 @default.
• W2021505546 hasConcept C170493617 @default.
• W2021505546 hasConcept C178853913 @default.
• W2021505546 hasConcept C185592680 @default.
• W2021505546 hasConcept C2776452961 @default.
• W2021505546 hasConcept C2777953023 @default.
• W2021505546 hasConcept C2778938600 @default.
• W2021505546 hasConcept C42219234 @default.
• W2021505546 hasConcept C58732023 @default.
• W2021505546 hasConcept C71924100 @default.
• W2021505546 hasConcept C84393581 @default.
• W2021505546 hasConceptScore W2021505546C125567185 @default.
• W2021505546 hasConceptScore W2021505546C126322002 @default.
• W2021505546 hasConceptScore W2021505546C170493617 @default.
• W2021505546 hasConceptScore W2021505546C178853913 @default.
• W2021505546 hasConceptScore W2021505546C185592680 @default.
• W2021505546 hasConceptScore W2021505546C2776452961 @default.
• W2021505546 hasConceptScore W2021505546C2777953023 @default.
• W2021505546 hasConceptScore W2021505546C2778938600 @default.
• W2021505546 hasConceptScore W2021505546C42219234 @default.
• W2021505546 hasConceptScore W2021505546C58732023 @default.
• W2021505546 hasConceptScore W2021505546C71924100 @default.
• W2021505546 hasConceptScore W2021505546C84393581 @default.
• W2021505546 hasIssue "5" @default.
• W2021505546 hasLocation W20215055461 @default.
• W2021505546 hasLocation W20215055462 @default.
• W2021505546 hasOpenAccess W2021505546 @default.
• W2021505546 hasPrimaryLocation W20215055461 @default.
• W2021505546 hasRelatedWork W2066859093 @default.
• W2021505546 hasRelatedWork W2195513968 @default.
• W2021505546 hasRelatedWork W2285354716 @default.
• W2021505546 hasRelatedWork W2314165071 @default.
• W2021505546 hasRelatedWork W2392249173 @default.
• W2021505546 hasRelatedWork W2582971951 @default.
• W2021505546 hasRelatedWork W2950761615 @default.
• W2021505546 hasRelatedWork W2977523330 @default.
• W2021505546 hasRelatedWork W2979617965 @default.
• W2021505546 hasRelatedWork W4220792475 @default.
• W2021505546 hasVolume "35" @default.
• W2021505546 isParatext "false" @default.
• W2021505546 isRetracted "false" @default.
• W2021505546 magId "2021505546" @default.
• W2021505546 workType "article" @default.